LJPC 401

Drug Profile

LJPC 401

Alternative Names: LJPC-401

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator INSERM
  • Developer INSERM; La Jolla Pharmaceutical Company
  • Class Anti-infectives; Antimicrobial cationic peptides; Peptide hormones; Peptides; Proteins
  • Mechanism of Action Hepcidin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia; Beta-thalassaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Iron overload

Most Recent Events

  • 01 Dec 2016 LJPC 401 receives Orphan Drug status for Sickle cell anaemia in European Union (La Jolla Pharma Annual report 2016)
  • 07 Sep 2016 Adverse events and efficacy data from a phase I trial in Iron overload released by La Jolla
  • 07 Sep 2016 La Jolla Pharmaceutical reaches an agreement with EMA on the design of pivotal trial in Iron Overload in Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top